Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials. - Terao I; Kodama W (PCN reports: psychiatry and clinical neurosciences, 2024)

Exploring Psychotherapeutic Benefits of Psilocybin and Psychedelics In Controlled Medical Settings - Arman Fard; Allison Cohen (Journal of Student Research, 2024)

Narrative review of psilocybin, an important psychoactive substance with potential peri-anesthetic implications - George Tewfik; Adejuyigbe Adaralegbe; Sangel Gomez; Rania Aziz; Faraz Chaudhry; Daniel Rodriguez-Correa; Dorisanne O. Adaralegbe (Trends in Anaesthesia and Critical Care, 2024)

A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient. - Morris SL (Clinical psychopharmacology and neuroscience: the official scientific journal of the Korean College of Neuropsychopharmacology, 2024)

Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration - Ben-Tal T; Pogodin I; Botvinnik A; Lifschytz T; Heresco-Levy U; Lerer B. (bioRxiv, 2024)

Neuroimaging of Serotonergic and Psychedelic Agonist Drug Challenges in Non-Human Primates - Ande Bagdasarian; Kristian Larsen; Patrick M. Fisher; Hanne D. Hansen; Hsiao-Ying Wey (Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition, 2024)

Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science. - Adams DR; Allen H; Nicol GE; Cabassa LJ (Translational behavioral medicine, 2024)

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression. - Aboharb F; Davoudian PA; Shao LX; Liao C; Rzepka GN; Wojtasiewicz C; Indajang J; Dibbs M; Rondeau J; Sherwood AM; Kaye AP; Kwan AC (bioRxiv: the preprint server for biology, 2024)

Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS) - Jaime Rojas-Hernández; Lucas F. Borkel; Domingo Jesús Quintana Hernández; Ángelo Santana del Pino; Luis Alberto Henríquez-Hernández (Current Psychology, 2024)

Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study. - Wood MJ; McAlpine RG; Kamboj SK (Scientific reports, 2024)

Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates. - Yale University (ClinicalTrials.gov, 2024)

A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder - TRYP Therapeutics (ClinicalTrials.gov, 2024)

Psilocybin Fungi Unveiled: Morphological Characteristics and Pharmacological Potentials - Raj Nashikkar; Kavita Mane; Rajendra Patil (International Journal for Research in Applied Science and Engineering Technology, 2024)

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals. - Wang E; Mathai DS; Gukasyan N; Nayak S; Garcia-Romeu A (Scientific reports, 2024)

Expanding the Therapeutic Horizons of Psilocybin in Mental Health. - Kargbo RB (ACS medicinal chemistry letters, 2024)

Psychedelic 5-HT2A receptor agonism: neuronal signatures and altered neurovascular coupling. - Padawer-Curry JA; Krentzman OJ; Kuo CC; Wang X; Bice AR; Nicol GE; Snyder AZ; Siegel JS; McCall JG; Bauer AQ (bioRxiv: the preprint server for biology, 2024)

PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related Burnout - University of Utah (ClinicalTrials.gov, 2024)

Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help - Stéphanie Knatz Peck; Hannah M. Fisher; Jessie Kim; Samantha Shao; Julie Trim; Walter H. Kaye (Psychedelics., 2024)

Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms - Hodge A; Forsyth A; Noorani T; Muthukumaraswamy S; Rolleston A; McHugh P. (PsyArXiv, 2024)

Long-term effects of psilocybin on dynamic and effectivity connectivity of fronto-striatal-thalamic circuits - Pasquini L; Vohryzek J; Escrichs A; Sanz Perl Y; Ponce-Alvarez A; Idesis S; Girn M; Roseman L; Mitchell JM; Gazzaley A; Kringelbach M; Nutt DJ; et al. (bioRxiv, 2024)

Amid magic and menace: psychiatrists' attitudes to psilocybin therapy. - Gribben A; Burke T; Harrington C; Husein A; Murnane KS; Hendricks PS; Tobin K; Ivers JH; Thuery G; Harkin A; Kelly JR (Irish journal of psychological medicine, 2024)

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics - Cristiano Chaves; Rafael G. dos Santos; Serdar Dursun; Massimo Tusconi; Mauro Giovanni Carta; Elisa Brietzke; Jaime E. C. Hallak (Frontiers in Psychiatry, 2024)

PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study) - Imperial College London (ClinicalTrials.gov, 2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders. - Valdez T; Patel V; Senesombath N; Hatahet-Donovan Z; Hornick M (Pharmaceuticals (Basel, Switzerland), 2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial - Aday JS; McAfee J; Conroy DA; Hosanagar A; Tarnal V; Weston C; Scott K; Horowitz D; Harte SE; Pouyan N; Glynos NG; Baker AK; et al. (PsyArXiv, 2024)

Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats. - Jeanblanc J; Bordy R; Fouquet G; Jeanblanc V; Naassila M (Brain: a journal of neurology, 2024)

Enhanced visual contrast suppression during peak psilocybin effects: Psychophysical results from a pilot randomized controlled trial. - Swanson LR; Jungers S; Varghese R; Cullen KR; Evans MD; Nielson JL; Schallmo MP (Journal of vision, 2024)

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial - Jacob S. Aday; Jenna McAfee; Deirdre A. Conroy; Avinash Hosanagar; Vijay Tarnal; Cody Weston; Katharine Scott; Dana Horowitz; Steven E. Harte; Niloufar Pouyan (PsyArXiv, 2024)

Pyramidal cell types and 5-HT receptors are essential for psilocybin's lasting drug action. - Shao LX; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu RJ; Woodburn SC; Bilash OM; Kim H; et al. (bioRxiv: the preprint server for biology, 2024)

Psilocybin alters the circulating metabolomic profile in both non-clinical and clinical models - Emese Prandovszky O’Donnell; Zachary A. Cordner; Hua Liu; Shuojia Yang; Lindsey Macias; Kellie L. Tamashiro; Frederick S. Barrett; Robert H. Yolken (Brain Behavior and Immunity, 2024)

Psilocybin-unterstützte Psychotherapie reduziert Ängste und Depressionen - Lamia Özgör (InFo Hämatologie + Onkologie, 2024)

Will Psychedelics Propel Your Career? Exploring the Potential Impact of Psychedelics on Work, Productivity and Well-Being - Jonathan Westover (Human capital leadership., 2024)

Phytochemical screening, phenolic and flavonoid contents, psilocybin, antioxidant, and acetylcholinesterase inhibition activities of the aqueous extract from the fungi Cyathus striatus, Laternea dringii, and Marasmius haematocephalus - D Silva; Antônio Carlos Pereira de Menezes Filho; Aurélio Ferreira Melo; Porshia Sharma; Tullyo Henrique Lima Machado; Vanêcia Oliveira Cunha Machado; Matheus Vinícius Abadia Ventura (Brazilian Journal of Science, 2024)

Novel treatments for anorexia nervosa: Insights from neuroplasticity research. - Keeler JL; Kan C; Treasure J; Himmerich H (European eating disorders review: the journal of the Eating Disorders Association, 2024)

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review. - Kim A; Halton B; Shah A; Seecof OM; Ross S (Annals of palliative medicine, 2024)

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice. - Pohořalá V; Kuchař M; Spanagel R; Bernardi RE (Neuroscience, 2024)

Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment. - Anderson K; Elf P; Isham A (The International journal on drug policy, 2024)

Psychoactive substances for the treatment of neuropsychiatric disorders. - Zhen Z; Sun X; Yuan S; Zhang J (Asian journal of psychiatry, 2024)

Psychedelic mushroom-containing chocolate exposures: Case series. - Gartner HT; Wan HZ; Simmons RE; Sollee DR; Sheikh S (The American journal of emergency medicine, 2024)

Psilocybin reduces functional correlation and the encoding of spatial information by neurons in mouse retrosplenial cortex. - Ivan VE; Tomàs-Cuesta DP; Esteves IM; Luczak A; Mohajerani M; McNaughton BL; Gruber AJ (The European journal of neuroscience, 2024)

The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists. - Imperio CG; Levin FR; Martinez D (The American journal of psychiatry, 2024)

Optimized psilocybin production in tryptophan catabolism-repressed fungi. - Janevska S; Weiser S; Huang Y; Lin J; Hoefgen S; Jojić K; Barber AE; Schäfer T; Fricke J; Hoffmeister D; Regestein L; Valiante V; et al. (Microbial biotechnology, 2024)

Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. - Reid MJ; Kettner H; Blanken TF; Weiss B; Carhart-Harris R (Current psychiatry reports, 2024)

[Depression and effectiveness of psychedelics: high-dose psilocybin has shown benefits in improving symptoms.]. - Forte V; Shaughnessy AF; Kurotschka PK (Recenti progressi in medicina, 2024)

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. - Petridis PD; Grinband J; Agin-Liebes G; Kinslow CJ; Zeifman RJ; Bogenschutz MP; Griffiths RR; Ross S (Nature. Mental health, 2024)

The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin - Holikulov Utkirjon; Kazachenko Aleksandr S.; Issaoui Noureddine; Kazachenko Anna S.; Raja Murugesan; Al-Dossary Omar M.; Xiang Zhouyang (Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts - Luoma JB; Wilson-Poe A; Pertl K; Hoffman K; Bazinet A; Stauffer C; McCarty D; Korthuis P. (PsyArXiv, 2024)

Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant's experience - Wahba M; Hayes C; Kletter M; McAllister-Williams RH (BJPsych Open, 2024)

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts - Jason Luoma; Adie Wilson-Poe; Kellie Pertl; Kim Hoffman; Alissa Bazinet; Christopher Stauffer; Dennis McCarty; Philip Korthuis (PsyArXiv, 2024)

A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study - Filament Health Corp. (ClinicalTrials.gov, 2024)

“The mushroom was more alive and vibrant”: Patient reports of synthetic versus organic forms of psilocybin - Pamela Kryskow; Paul Stamets; Joseph La Torre; Kathy Sattler; Vivian W. L. Tsang; Monnica T. Williams (Journal of Psychedelic Studies, 2024)

Psilocin, the Psychoactive Metabolite of Psilocybin, Modulates Select Neuroimmune Functions of Microglial Cells in a 5-HT2 Receptor-Dependent Manner - Wiens Kennedy R.; Brooks Noah A. H.; Riar Ishvin; Greuel Bridget K.; Lindhout Ivan A.; Klegeris Andis (Molecules, 2024)

Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms - Imperial College London (ClinicalTrials.gov, 2024)

Psilocybin Reduces Grooming in the SAPAP3 Knockout Mouse Model of Compulsive Behaviour - Gattuso JJ; Wilson C; Hannan AJ; Renoir T. (bioRxiv, 2024)

Expert recommendations for Germany's integration of psychedelic-assisted therapy. - Perez Rosal SR; La Torre JT; Birnkammer S; Chernoloz O; Williams MT; Faber SC (BMC medical education, 2024)

Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration - Mott; Sarah E.; Clyde W. Hodge; Jessica L. Hoffman; Maria Echeveste Sanchez; Christian S. Rollison; Margaret W. High; Devin P. Effinger; Melissa A. Herman; Sarah N. Magee; Daniel Toedt; Sema G. Quadir (UNC Libraries, 2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics - Majic T; Schmidt TT; Gröticke A; Gasser P; Richards WA; Riemer TG; Evens R. (PsyArXiv, 2024)

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin - Mallaroni P; Singleton P; Mason NL; Satterthwaite TD; Ramaekers JG. (bioRxiv, 2024)

The Afterglow Inventory (AGI) - validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics - Tomislav Majic; Timo Torsten Schmidt; Anna Gröticke; Peter Gasser; William A Richards; Thomas Günther Riemer; Ricarda Evens (PsyArXiv, 2024)

The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice - Fleury S; Nautiyal KM. (bioRxiv, 2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. - Hooper J; Gyongyosi E; Hutchison K; Mueller R. (PsyArXiv, 2024)

Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes. - Jake Hooper; Emily Gyongyosi; Kent Hutchison; Raeghan Mueller (PsyArXiv, 2024)

Effects of classical psychedelics on implicit and explicit emotional empathy and cognitive empathy: a meta-analysis of MET task. - Olami A; Peled-Avron L (Scientific reports, 2024)

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders - Valdez T; Patel V; Senesombath D; Hatahet-Donovan Z; Hornick MG. (Preprints.org, 2024)

An Early Exploration into Individuals in Treatment Who Co-Use Alcohol and Hallucinogens - Ivy Fitzsimons; Andrew J. Moore; Sara Jo Nixon (UF Journal of Undergraduate Research, 2024)

Psilocybin-assisted psychotherapy as an ‘anti-distressant’ with multidimensional properties - Danica E. Johnson; Joshua D. Rosenblat (Nature Mental Health, 2024)

Human brain changes after first psilocybin use - Lyons T; Spriggs M; Kerkelä L; Rosas F; Roseman L; Mediano P; Timmermann C; Oestreich L; Pagni B; Zeifman R; Hampshire A; Trender W; et al. (bioRxiv, 2024)

Impact of Protonation Sites on Collision-Induced Dissociation-MS/MS Using CIDMD Quantum Chemistry Modeling. - Lee J; Tantillo DJ; Wang LP; Fiehn O (Journal of chemical information and modeling, 2024)

A survey investigating United States federal grant submissions proposing to investigate therapeutic applications of psychedelics - Barnett BS. (medRxiv, 2024)

Snapshot of 5-HT receptor activation in the mouse brain via IP detection. - de la Fuente Revenga M; González-Maeso J (bioRxiv: the preprint server for biology, 2024)

The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment - Hannah Douglass (Open MIND, 2024)

Does psilocybin reduce symptoms of depression in adults with major depressive disorder or life-threatening cancer? - Morgan Justin; Kerry Watrin (Evidence-Based Practice, 2024)

Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study - James Rucker; Matthew Butler; Sadie Hambleton; Catherine Bird; Mathieu Seynaeve; Sanjay Cheema; Kete Campbell-Coker; Carolina Maggio; Fiona Dunbar; Giorgio Lambru; Manjit Matharu (Headache The Journal of Head and Face Pain, 2024)

A psilocybin haven: the use of comparison to legitimate transgression at a psychedelic retreat - Jesper Dunell (Drugs Education Prevention and Policy, 2024)

Memory, trauma, and self: Remembering and recovering from sexual abuse in psychedelic-assisted therapy - Jarrett Robert Rose (Journal of Psychedelic Studies, 2024)

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2024)

Neuroprotective effects of psilocybin in a rat model of stroke. - Yu SJ; Wu KJ; Wang YS; Bae E; Chianelli F; Bambakidis N; Wang Y (BMC neuroscience, 2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol - Pincombe J; Williams M; Carruthers S; Rossell S. (PsyArXiv, 2024)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol - Jennifer Pincombe; Martin Williams; Sean Carruthers; Susan Rossell (PsyArXiv, 2024)

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome. - Dahan JDC; Dadiomov D; Bostoen T; Dahan A (Npj mental health research, 2024)

Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis - Dimy Fluyau; Vasanth Kattalai Kailasam; Neelambika Revadigar (Psychoactives, 2024)

PR012/#955 Psilocybin assisted psychotherapy for patients with ovarian caner: a subset analysis of a randomized, double-blind, placebo-controlled, phase II clinical trial - Daniel Spinosa; Stacy M. Fischer; Richard J. Zeifman; Carolyn Lefkowits; Petros Petridis; Stephen Ross (International Journal of Gynecological Cancer, 2024)

From efficacy to effectiveness: evaluating psychedelic randomised controlled trials for trustworthy evidence-based policy and practice. - Schenberg EE. (PsyArXiv, 2024)

Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms. - Conn K; Milton LK; Huang K; Munguba H; Ruuska J; Lemus MB; Greaves E; Homman-Ludiye J; Oldfield BJ; Foldi CJ (Molecular psychiatry, 2024)

Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms. - Rakoczy RJ; Runge GN; Sen AK; Sandoval O; Wells HG; Nguyen Q; Roberts BR; Sciortino JH; Gibbons WJ; Friedberg LM; Jones JA; McMurray MS (British journal of pharmacology, 2024)

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. - Nadeem Z; Parker S; McGovern H; Oestreich LK (The Australian and New Zealand journal of psychiatry, 2024)

Psilocybin and 2C-B at Encoding Distort Episodic Familiarity. - Doss MK; Mallaroni P; Mason NL; Ramaekers JG (Biological psychiatry. Cognitive neuroscience and neuroimaging, 2024)

Effects of psilocybin on body weight, body composition, and metabolites in male and female mice. - Shakir J; Pedicini M; Bullock BC; Hoen PW; Macias LK; Freiman J; Pletnikov MV; Tamashiro KLK; Cordner ZA (Physiology & behavior, 2024)

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges. - Gomez-Escolar A; Folch-Sanchez D; Stefaniuk J; Swithenbank Z; Nisa A; Braddick F; Idrees Chaudhary N; van der Meer PB; Batalla A (CNS drugs, 2024)

Psilocybin in pharmacotherapy of obsessive-compulsive disorder. - Owe-Larsson M; Kamińska K; Buchalska B; Mirowska-Guzel D; Cudnoch-Jędrzejewska A (Pharmacological reports: PR, 2024)

Psilocybin for clinical indications: A scoping review. - Madden K; Flood B; Young Shing D; Ade-Conde M; Kashir I; Mark M; MacKillop J; Bhandari M; Adili A (Journal of psychopharmacology (Oxford, England), 2024)

Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire. - Hovmand OR; Madsen MK; Fisher PM; Stenbæk DS (Journal of psychopharmacology (Oxford, England), 2024)

Letter to editor regarding "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis". - Yang X; Kuang W (Psychiatry research, 2024)

The role of psilocybin in depressive disorders. - Najib J (Current medical research and opinion, 2024)

Less is more? A review of psilocybin microdosing. - Savides IA; Outhoff K (Journal of psychopharmacology (Oxford, England), 2024)

Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response. - Calder AE; Rausch B; Liechti ME; Holze F; Hasler G (Journal of psychopharmacology (Oxford, England), 2024)

Artificial intelligence and psychedelic medicine. - Sarris J; Halman A; Urokohara A; Lehrner M; Perkins D (Annals of the New York Academy of Sciences, 2024)

Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat. - Meling D; Egger K; Aicher HD; Jareño Redondo J; Mueller J; Dornbierer J; Temperli E; Vasella EA; Caflisch L; Pfeiffer DJ; Schlomberg JT; Smallridge JW; et al. (Journal of psychopharmacology (Oxford, England), 2024)

What do health professionals think about implementing psilocybin-assisted therapy in palliative care for existential distress? A World Café qualitative study. - Masse-Grenier M; Chang SL; Bélanger A; Stephan JF; Hébert J; Deschamps P; Plourde L; Provost F; Farzin H; Fallu JS; Dorval M; P3A Research Group (Palliative & supportive care, 2024)

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. - Erritzoe D; Barba T; Greenway KT; Murphy R; Martell J; Giribaldi B; Timmermann C; Murphy-Beiner A; Jones MB; Nutt D; Weiss B; Carhart-Harris R (EClinicalMedicine, 2024)

What should constitute a control condition in psychedelic drug trials? - Colloca L; Fava M (Nature. Mental health, 2024)

Psilocybin prevents habituation to familiar stimuli and preserves sensitivity to sound following repeated stimulation in mouse primary auditory cortex - Lane CP; Tarka VM; Valentin O; Lehmann A; Hamel E; de Villers-Sidani E. (bioRxiv, 2024)

Psilocybin increases optimistic engagement over time: computational modelling of behaviour in rats. - Fisher EL; Smith R; Conn K; Corcoran AW; Milton LK; Hohwy J; Foldi CJ (Translational psychiatry, 2024)

Beyond the numbers: reimagining healing with psychedelics for eating disorders. - Lafrance A; Spriggs MJ; Gukasyan N; Peck SK (Journal of eating disorders, 2024)

The Action on Psilocybin in Neural Plasticity, Brain Reorganization and Cognitive Enhancement - Carlos Henrique Marchiori; Marco Vinícios de Oliveira Santana; Klebert de Paula Malheiros (Middle East Research Journal of Biological Sciences, 2024)

The Effects of Psilocybin on Shared Experience in Film Processing - Western University; Canada (ClinicalTrials.gov, 2024)

Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative study - Aleš Oblak; Liam Korošec Hudnik; Anja Levačić; Kristian Elersič; Peter Pregelj; Jurij Bon (Philosophical Psychology, 2024)

Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity - Allohverdi S; Soltanzadeh M; Schmidt A; Charlton C; Hauke D; Karvelis P; Vollenweider F; Diaconescu A. (Research Square, 2024)

An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder - University of California; San Francisco (ClinicalTrials.gov, 2024)

Psychedelics as novel therapeutic agents for chronic pain: mechanisms and future perspectives - Bushra Yasin; Shivani Mehta; George Tewfik; Alex Bekker (Exploration of neuroscience, 2024)

Distinct classes of antidepressants commonly act to shape pallidal structure and function in mice - Abe Y; Sugiura Y; Maeda R; Taira S; Yoshida K; Ibi D; Moritoh S; Hashimoto K; Yagishita S; Tanaka KF. (bioRxiv, 2024)

Psilocybin legalization in the United States and psychological reactance: A test of evidence uncertainty, controlling language, and an ambiguous call to action. - Brian L. Quick; Ethan Morrow; Sam R. Wilson; Minhey Chung; Daniel E. Hartman; Brenda Koester (Motivation Science, 2024)

Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment - Lazar M; Brownstien M; Botvinnik A; Shevakh C; Shahar O; Lifschytz T; Lerer B. (bioRxiv, 2024)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans - Larsen K; Lindberg U; Ozenne B; McCulloch DE; Armand S; Madsen MK; Johansen A; Stenbæk DS; Knudsen GM; Fisher PM. (medRxiv, 2024)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates the gabapentin-mediated analgesia - Askey T; Allen-Ross D; Lasrado R; Gilmour G; Hunt S; Tamagnini F; Ahmed M; Stephens G; Maiarú M. (Research Square, 2024)

Psychedelic research at a crossroads. - Armstrong SB; Davis AK (Science (New York, N.Y.), 2024)

Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus - University Hospital; Ghent (ClinicalTrials.gov, 2024)

Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress - Mageean S; Daniel A; Tai S. (Research Square, 2024)

Psychedelics as a potential treatment for tobacco use disorder: a systematic review. - Spoelstra SK; Schoevers RA; Venema SD; Knegtering H (Discover mental health, 2024)

Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials - Danielle B Rodrigues (Journal of Complementary Medicine & Alternative Healthcare, 2024)

The Psychedelic Renaissance: A Catholic Perspective - Thomas Carroll (The Linacre Quarterly, 2024)

An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States - Syed F. Rab; Charles L. Raison; Elliot Marseille (Psychedelics., 2024)

B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations - James Perry; Cara C. Young; Julie Williams (Archives of Clinical Neuropsychology, 2024)

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. - Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C (The Cochrane database of systematic reviews, 2024)

Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience. - Kargbo RB (ACS medicinal chemistry letters, 2024)

Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine. - Kargbo RB (ACS medicinal chemistry letters, 2024)

The Epidemiology of Psychedelic Use Among United States Military Veterans - Alan K. Davis; Mark J. Bates; Erik M. Lund; Nathan D. Sepeda; Adam W. Levin; Stacey B. Armstrong; Robert L. Koffman; Katinka Hooyer; Rachel Yehuda (Journal of Psychoactive Drugs, 2024)

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner - Nikolic M; Mediano P; Froese T; Reydellet D; Palenicek T. (medRxiv, 2024)

Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms - Ana Ferreira; Sharon Martindale; David Luke (Journal of Psychedelic Studies, 2024)

Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol - Cynthia Duan; Navid Farkhondehpay; Viana Safa; Emma Yuan (Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 2024)

Psychedelic-assisted therapy: Magical thinking or a meaningful treatment for mental illness - Megha Kodancha (UCC Student Medical Journal, 2024)

Psilocybin-induzierte mystische Erfahrungen in subjektiven Berichten: Ein Scoping Review mit qualitativer Inhaltsanalyse. - Anna Graue; Sören Kuitunen-Paul; Henry G. Harder; Lisa Emily Richter (Suchttherapie, 2024)

Einmalig Psilocybin: antidepressive Effekte - Arnim Quante (PSYCH up2date, 2024)

Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine - Albert Garcia-Romeu (Psychedelic Medicine, 2024)

Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review. - Gattuso JJ; Wilson C; Hannan AJ; Renoir T (Journal of neurochemistry, 2024)

Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. - Köhne S; Hillemacher T; Glahn A; Bach P (Expert opinion on emerging drugs, 2024)

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia. - Darke S; Duflou J; Peacock A; Farrell M; Hall W; Lappin J (Addiction (Abingdon, England), 2024)

Stutterers' experiences on classic psychedelics: A preliminary self-report study. - Jackson ES; Goldway N; Gerlach-Houck H; Gold ND (Journal of fluency disorders, 2024)

Commentary on Darke et al.: Expanded psychedelic access requires new safety monitoring systems. - Korthuis PT; Wilson-Poe AR; Black JC; Monte A (Addiction (Abingdon, England), 2024)

Effects of psilocybin on uncertain punishment learning. - Jacobs DS; Bogachuk AP; Le Moing CL; Moghaddam B (Neurobiology of learning and memory, 2024)

Psilocybin: Medicine for My Soul. Relief from Emotional and Spiritual Pain as a Hospice Nurse Diagnosed with Cancer. - Clark MP (Journal of palliative medicine, 2024)

Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. - Guo Q; Guo L; Wang Y; Shang S (Psychiatry research, 2024)

Psilocybin desynchronization persists in the human brain. - Rogers J (Nature reviews. Neuroscience, 2024)

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis. - Caspani G; Ruffell SGD; Tsang W; Netzband N; Rohani-Shukla C; Swann JR; Jefferies WA (Pharmacological research, 2024)

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment]. - Jungwirth J; Bavato F; Quednow BB (Der Nervenarzt, 2024)

Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report. - Federico S; Geo M; Entela M; Bachmann S; Elisa R; Silvio C; Zoë D; Louise P; Gabriel T; Joël B; Daniele Z (Clinical case reports, 2024)

Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin? - Treviranus GRS (Psychiatria Danubina, 2024)

Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders. - Loizaga-Velder A; Loizaga Pazzi A (Journal of studies on alcohol and drugs, 2024)

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis. - Smith CL; Sackett N; Stark BC; Dinh V; Romesburg EW; Roll J (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Refractory CRPS pain treated with psilocybin: A case report. - Jevotovsky DS; Chopra H; Wing C; Spotswood CJ; Castellanos J (Clinical case reports, 2024)

G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included? - Amany E. Ayad (Ask the expert - Psychedelic substances, 2024)

Psilocybin for Treatment of Obsessive Compulsive Disorder - University of Arizona (ClinicalTrials.gov, 2024)

Mystical Experience with Cancer Patients: Insights from Psychedelic-Assisted Psychotherapy and Guided Imagery - Jerry B. Brown *; Julie M. Brown (Clinical Endocrinology and Metabolism, 2024)

The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance - Yoo M; Sakopoulos S. (Authorea Preprints, 2024)

Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing - Charlotte Smith (Journal of Management Inquiry, 2024)

Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection. - Yao Y; Zhang YZ; Liang JQ; Liu F; Li ZF; Li HJ; Xu F (Toxicon: official journal of the International Society on Toxinology, 2024)

A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis - Tsang V. (European psychiatry: the journal of the Association of European Psychiatrists, 2024)

Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations - Tsang V; Roney C. (European psychiatry: the journal of the Association of European Psychiatrists, 2024)

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting - Klučková T; Nikolič M; Tylš F; Viktorin V; Vejmola Č; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Zach P; Hájková K; et al. (medRxiv, 2024)

Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse: A Cautionary Tale. - Frye MA; Singh B; Breitinger SA; Oesterle TS (The Journal of clinical psychiatry, 2024)

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study - Jensen ME; Stenbæk DS; Messell CD; Poulsen ED; Varga TV; Fisher PM; Nielsen MKK; Johansen SS; Volkow ND; Knudsen GM; Fink-Jensen A. (Research Square, 2024)

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. - Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS (BMJ (Clinical research ed.), 2024)

Psilocybin, moralization and psychotherapy: a scoping review and a case report - Emiliano Loria; Elisabetta Lalumera; Ambra D’Imperio (Philosophical Psychology, 2024)

Psilocybin in the Treatment of Mental Disorders - Doğancan Sönmez; Aslı Enzel Koç (DergiPark (Istanbul University), 2024)

Tripping on Utopia: Margaret Mead, the Cold War, and the troubled birth of psychedelic science By BenjaminBreen. New York: Grand Central Publishing, 2024. 384 pp. - Jim Weil (American Anthropologist, 2024)

A virtual clinical trial of psychedelics to treat patients with disorders of consciousness - Alnagger NL; Cardone P; Martial C; Sanz Perl Y; Mindlin I; Sitt JD; Roseman L; Carhart-Harris R; Nutt D; Mallaroni P; Mason NL; Ramaekers JG; et al. (bioRxiv, 2024)

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. - Salvetti G; Saccenti D; Moro AS; Lamanna J; Ferro M (Brain sciences, 2024)

Psychedelic use and psychological flexibility: The role of meaningful intention and decentering - William M. Campo; Ann Marie Yali (Journal of Psychedelic Studies, 2024)

A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) - Clairvoyant Therapeutics (ClinicalTrials.gov, 2024)

Prevalence and Correlates of Psychedelic Use in Poland: A Study on a Representative Sample of Polish Adults - Holas P; Kaminska J. (Research Square, 2024)

Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity - Frederick A. Bagdasarian; Hanne D. Hansen; Chi-Hyeon Yoo; Michael S. Placzek; Jacob M. Hooker; Hsiao-Ying Wey (Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition, 2024)

Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression - Rodolfo Myronn de Melo Rodrigues (Psychedelics., 2024)

Resurrecting Ancestral Familial Health: A Role for Psilocybin? - Ashley Glowiak (The Family Journal, 2024)

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) - Sheppard Pratt Health System (ClinicalTrials.gov, 2024)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium - Vella Y; Syrova K; Petruskova A; Koutrouli I; Kutna V; Pala J; Nikolic M; Sichova K; Mazoch V; Jurok R; Kuchar M; Bendova Z; et al. (bioRxiv, 2024)

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms - Brugmann University Hospital (ClinicalTrials.gov, 2024)

Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression - Gustavo Deco; Yonatan Sanz Perl; Samuel Johnson; Niamh Bourke; Robin Carhart-Harris; Morten L. Kringelbach (Nature Mental Health, 2024)

Psilocybin-assisted therapy and HIV-related shame. - Mehtani NJ; Johnson MO; Hendricks PS; Mitchell J; Anderson BT (Scientific reports, 2024)

Insights into the efficacy of psilocybin in treating depression and other disorders - Sarah Jane Palmer (British Journal of Neuroscience Nursing, 2024)

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study - Véliz-García O; Domic M. (Research Square, 2024)

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. - Kaminski D; Reinert JP (The Annals of pharmacotherapy, 2024)

Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions. - Tipado Z; Kuypers KPC; Sorger B; Ramaekers JG (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2024)

Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. - Sakai K; Bradley ER; Zamaria JA; Agin-Liebes G; Kelley DP; Fish A; Martini V; Ferris MC; Morton E; Michalak EE; O'Donovan A; Woolley JD (Psychopharmacology, 2024)

Is it now time to prepare psychiatry for a psychedelic future? - Nutt D; Crome I; Young AH (The British journal of psychiatry: the journal of mental science, 2024)

Psychedelic-assisted psychotherapy: where is the psychotherapy research? - Aday JS; Horton D; Fernandes-Osterhold G; O'Donovan A; Bradley ER; Rosen RC; Woolley JD (Psychopharmacology, 2024)

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. - Chisamore N; Johnson D; Chen MJQ; Offman H; Chen-Li D; Kaczmarek ES; Doyle Z; McIntyre RS; Rosenblat JD (Journal of psychiatric research, 2024)

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. - Polito V; Liknaitzky P (Journal of psychopharmacology (Oxford, England), 2024)

The cyclical revival of psychedelics in psychiatric treatment. - Appiani FJ; Caroff SN (Current medical research and opinion, 2024)

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study. - Korthuis PT; Hoffman K; Wilson-Poe AR; Luoma JB; Bazinet A; Pertl K; Morgan DL; Cook RR; Bielavitz S; Myers R; Wolf RC; McCarty D; et al. (Journal of psychopharmacology (Oxford, England), 2024)

The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world. - Lake S; Lucas P (The International journal on drug policy, 2024)

Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness. - Mograbi DC; Rodrigues R; Bienemann B; Huntley J (Current neurology and neuroscience reports, 2024)

Psilocybin desynchronizes the human brain. - Siegel JS; Subramanian S; Perry D; Kay BP; Gordon EM; Laumann TO; Reneau TR; Metcalf NV; Chacko RV; Gratton C; Horan C; Krimmel SR; et al. (Nature, 2024)

CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS. - Kaiserman A; Vanderjist L; Kornreich C (Psychiatria Danubina, 2024)

Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method - Khajavinia Amir; Michel Deborah; Ezeaka Udoka C.; Purves Randy W.; Laprairie Robert B.; El-Aneed Anas (Journal of Chromatography A, 2024)

Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients - V Suresh; Jitendra Lakhani; R Balaraman (Journal of Natural Remedies, 2024)

How psilocybin affects the brain. - O'Leary K (Nature medicine, 2024)

Expanding Mindscapes: A Global History of Psychedelics. By ErikaDyck, ChrisElcock (Eds.), Cambridge, MA: The MIT Press. 2023. ISBN: 9780262546935 - Peder Clark (Addiction, 2024)